Ocuphire PharmaOCUP
Market Cap: $38.2M
About: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Employees: 14
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
3.57% less ownership
Funds ownership: 13.97% [Q1] → 10.4% (-3.57%) [Q2]
24% less funds holding
Funds holding: 49 [Q1] → 37 (-12) [Q2]
41% less capital invested
Capital invested by funds: $6.97M [Q1] → $4.13M (-$2.84M) [Q2]
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Matthew Caufield 36% 1-year accuracy 15 / 42 met price target | 1,133%upside $18 | Buy Maintained | 15 Aug 2024 |
Canaccord Genuity John Newman 74% 1-year accuracy 14 / 19 met price target | 1,133%upside $18 | Buy Maintained | 14 Aug 2024 |